We invite you to explore the emerging intersections of psychedelic medicine and chronic pain care in our next Community Forum, which will examine how psychedelic-assisted approaches to pain may both align with and challenge existing mental health treatment models. As interest in psychedelic therapies continues to grow, important questions remain about how these interventions work in the context of long-term pain conditions, and whether current frameworks adequately address the realities faced by people living with chronic pain. We’ll discuss the mechanisms through which psychedelics may influence pain, whether by reducing pain itself, transforming the relationship individuals have with pain, or improving overall quality of life. What role do factors such as dose, intensity of experience, and therapeutic support play in pain outcomes? Do all patients benefit from traditional talk-therapy models as part of care? And as the field advances, how can clinicians, researchers, educators, and patient advocates work together to develop responsible, evidence-based models of care? We’ll also discuss the key issue of how to communicate both the promise and the limitations of psychedelic therapies without creating unrealistic expectations for those living with serious pain. You’ll hear from Joe Moore, co-founder and CEO of Psychedelics Today; Tess Veuthey, neurologist and pain physician; and Jagpaul Kaur Deol, Clinical Advisor with TheraPsil and member of MAPS Canada Board of Directors; in a conversation moderated by Lorien Chavez, Development and Operations Officer for the Chacruna Institute.

Psychedelics and the Future of Pain Care